CD135 (Flt3) Monoclonal Antibody (A2F10), PE-Cyanine5, eBioscience™, Invitrogen™

Description

• Description: The A2F10 monoclonal antibody reacts with mouse CD135, also known as Flk2/Flt3
• A member of the tyrosine kinase receptor family, this 135-150 kDa molecule is expressed by primitive progenitor cells in fetal liver and adult bone marrow
• Two-color staining of adult mouse bone marrow cells with A2F10 and RA3-6B2 (CD45R/B220) or M1/70 (CD11b) reveals Flk-2-positive subpopulations of B cells or myeloid cells, respectively
• Applications Reported: This A2F10 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This A2F10 antibody has been tested by flow cytometric analysis of mouse bone marrow cells
• This can be used at less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Light sensitivity: This tandem dye is sensitive photo-induced oxidation
• Please protect this vial and stained samples from light
• Fixation: Samples can be stored in IC Fixation Buffer (cat
• 00-8222) (100 μL cell sample + 100 μL IC Fixation Buffer) or 1-step Fix/Lyse Solution (cat
• 00-5333) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation
• FLT3 is a tyrosine protein kinase that is a member of the growth factor receptor tyrosine kinase family
• The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor
• The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow
• Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.